For clients who have experienced facial volume loss or skin looseness associated with GLP-1-related weight loss, XERF can be an effective part of a comprehensive skin restoration strategy
They include: Nausea the most commonly reported symptom, typically peaking in the first one to two weeks after a dose change Diarrhoea and constipation both can occur, sometimes alternating Vomiting less common than nausea but reported by some patients at higher doses Abdominal discomfort or bloating Diet-related side effects occur when patients eat too little, too quickly, or consume high-fat meals
Wegovy and cardiovascular risk reduction In March 2024, the FDA approved Wegovy to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight
The mass fingerprints were generated and searched against the SwissProt database protein (European Bioinformatics Institute, Cambridge, UK) database using the MASCOT search engine (Matrix Science, London, UK)
